147 related articles for article (PubMed ID: 18825163)
21. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
Roehrborn CG
Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
23. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia.
Vikram A; Jena GB; Ramarao P
Prostate; 2010 Jan; 70(1):79-89. PubMed ID: 19790233
[TBL] [Abstract][Full Text] [Related]
24. [Insulin-like growth factor (IGF-1) and the clinical course of prostate cancer, benign hyperplasia and prostatic intraepithelial neoplasia].
Povelitsa EA; Nabyrov EA
Vopr Onkol; 2008; 54(5):596-601. PubMed ID: 19069473
[TBL] [Abstract][Full Text] [Related]
25. Alcohol consumption decreases risk of BPH.
Rees J
Practitioner; 2009 Dec; 253(1724):5, 3. PubMed ID: 20120825
[TBL] [Abstract][Full Text] [Related]
26. [Data analysis of the objective observation parameters of benign prostatic hyperplasia patients accepting different treatment regimens].
Zhang YG; Wang JY; Liu M; Wan B; Wei D; Deng SM; Xu J; Wu JY; Chu X; Zeng P
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1690-2. PubMed ID: 19024540
[TBL] [Abstract][Full Text] [Related]
27. [Antagonistic effect of 3'-daidzein sulfonate sodium on prostatic hyperplasia in mice].
Huang YS; Zeng J; Huang YP; Qiu F; Ye HY; Wang SR
Zhonghua Nan Ke Xue; 2007 May; 13(5):387-90. PubMed ID: 17569249
[TBL] [Abstract][Full Text] [Related]
28. The role of cigarette smoking in prostatic enlargement.
Küpeli B; Soygür T; Aydos K; Ozdiler E; Küpeli S
Br J Urol; 1997 Aug; 80(2):201-4. PubMed ID: 9284188
[TBL] [Abstract][Full Text] [Related]
29. Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels.
Soygür T; Küpeli B; Aydos K; Küpeli S; Arikan N; Müftüoğlu YZ
Int Urol Nephrol; 1996; 28(1):55-9. PubMed ID: 8738620
[TBL] [Abstract][Full Text] [Related]
30. The single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS-BPH).
Chen ZP; Yan Y; Chen CJ; Li M; Chen C; Zhao SC; Song T; Liu T; Zou CH; Xu Q; Li X
Andrology; 2018 Jul; 6(4):568-578. PubMed ID: 29873201
[TBL] [Abstract][Full Text] [Related]
31. Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration.
Suzuki K; Ito K; Ichinose Y; Kurokawa K; Suzuki T; Imai K; Yamanaka H; Honma S
Scand J Urol Nephrol; 1995 Mar; 29(1):65-8. PubMed ID: 7542400
[TBL] [Abstract][Full Text] [Related]
32. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
33. [Further studies on the relationship between benign prostatic hyperplasia and prostatitis].
Xia T
Zhonghua Nan Ke Xue; 2004 Feb; 10(2):83-5. PubMed ID: 15027176
[TBL] [Abstract][Full Text] [Related]
34. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results.
Brisinda G; Cadeddu F; Vanella S; Mazzeo P; Marniga G; Maria G
Urology; 2009 Jan; 73(1):90-4. PubMed ID: 18995889
[TBL] [Abstract][Full Text] [Related]
35. Re: Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia.
Rohrmann S; Platz EA; Smit E; Giovannucci E
J Urol; 2004 Aug; 172(2):779. PubMed ID: 15247791
[No Abstract] [Full Text] [Related]
36. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia.
Liu L; Li Q; Han P; Li X; Zeng H; Zhu Y; Wei Q
Urology; 2009 Aug; 74(2):340-4. PubMed ID: 19464042
[TBL] [Abstract][Full Text] [Related]
37. Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome.
Kowalska I; Straczkowski M; Nikolajuk A; Adamska A; Karczewska-Kupczewska M; Otziomek E; Kinalska I; Gorska M
Metabolism; 2008 Nov; 57(11):1539-44. PubMed ID: 18940391
[TBL] [Abstract][Full Text] [Related]
38. Association of codon 10 polymorphism of the transforming growth factor beta 1 gene with prostate cancer and hyperplasia in an Iranian population.
Omrani MD; Taghipour-Bazargani S; Salari-Lak S; Bagheri M
Urol Int; 2009; 83(3):329-32. PubMed ID: 19829035
[TBL] [Abstract][Full Text] [Related]
39. [Study on patients with benign prostate hyperplasia treated by the therapeutic regimen of watchful waiting during a twenty-four-month follow-up period].
Zhang YG; Wang JY; Liu M; Xu J; Wu JY; Xin Y; Wan B; Wei D; Zhu SC; Zeng P
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):611-3. PubMed ID: 19040049
[TBL] [Abstract][Full Text] [Related]
40. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
